Coronary Sinus Reducer for Angina Without Blocked Arteries
Official title: Coronary Sinus Reducer in Patients With Angina With no Obstructive Coronary Disease: a Prospective Single-arm Study
Run by Medical University of Warsaw · NCT07010029 · Data updated 2026-11-12
This trial tests whether placing a coronary sinus reducer device can relieve angina in people who have chest pain but no significant coronary artery blockages and confirmed microvascular dysfunction.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Medical University of Warsaw Academic / other |
| Locations | 1 site (Warsaw) |
| Status | Recruiting |
| Started | May 12, 2025 |
| Main results expected | May 2027 |
| Study ends | August 2027 |
| Registry record updated | June 8, 2025 |
| Trial ID | NCT07010029 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with stable angina, no significant coronary artery stenosis, invasive-confirmed coronary microvascular dysfunction (CFR ≤ 2.5 or IMR ≥ 25), and persistent symptoms despite maximal antianginal therapy for at least three months.
✕Probably not a fit
Patients with vasospastic angina, severe valvular disease, significant heart failure (EF ≤ 30%), recent acute coronary events, permanent right-sided pacing/defibrillator leads, or other listed exclusions are unlikely to benefit from this device.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial implants a coronary sinus reducer to narrow the coronary sinus and raise venous pressure in the heart, aiming to alter myocardial perfusion for symptom relief. Participants must have stable angina without significant epicardial stenosis and invasive confirmation of coronary microvascular dysfunction (CFR ≤ 2.5 or IMR ≥ 25) after at least three months of maximal antianginal therapy. Key exclusions include vasospastic angina, significant valvular disease, severe left ventricular dysfunction (EF ≤ 30%), recent acute coronary syndrome or revascularization, and other conditions that increase procedural risk. The study will track changes in symptoms and microvascular physiological indices, building on limited observational data suggesting benefit.
Why it matters
Potential benefit: If successful, the device could reduce angina symptoms and improve quality of life for patients with microvascular angina who have no options left from medications.
How similar studies have gone: Observational studies and prior use of the coronary sinus reducer in patients with obstructive coronary disease have reported symptomatic improvement, but randomized evidence in microvascular angina is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Stable angina symptoms without significant obstruction of coronary artery (defined as coronary artery stenosis diameter ≤ 50% or coronary artery stenosis diameter \>50% and ≤70% with FFR\>0.8), with coronary microvascular dysfunction confirmed in invasive test (defined as coronary flow reserve ≤ 2.5 or index of microvascular resistance ≥ 25) * No future options for antianginal therapy (maximum antianginal therapy for at least three months) Exclusion Criteria: * Vasospastic angina (positive test with acetylcholine), * Evidence of cardiac ischemia, * Coronary flow limiting myocardial bridge, * Severe valvular disease * Hospitalization for acute heart failure \< 3 months * Hypertrophic cardiomyopathy, * Ejection fraction ≤ 30%, * Permanent pacemaker or defibrillator leads in the right heart, * Recent acute coronary syndrome \< 6 months, * Recent revascularization \< 2 months, * Right atrial pressure of 15 mmHg or higher, * Severe renal impairment, * Indication for cardiac resynchronization therapy, * Pregnancy, * Life expectancy of less than 1 year, * Inclusion in another clinical trial
Where it's running
-
Medical University of Warsaw
Warsaw, Poland Recruiting
Study contacts
- Study coordinator: Mariusz Tomaniak, Professor
- Email: mariusz.tomaniak@wum.edu.pl
- Phone: +48 22 5991951
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comprehensive coronary physiology testing for adults with angina but no blocked coronary arteries in the Czech Republic
This project will test detailed invasive coronary physiology and vasospasm tests in adults who have angina but no major coronary blockages to see if microvascular dysfunction or spasms explain their symptoms.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
TSLP in asthma: comparing long and short forms in adults with atopic or severe asthma
Researchers are testing whether levels of two TSLP forms in adults with asthma relate to disease severity and airway inflammation.
-
Body-focused mindfulness added to inpatient alcohol use disorder treatment
This trial tests whether a body-focused mindfulness program can help people with alcohol use disorder feel more connected to their bodies and reduce cravings while in inpatient care.
-
Remineralizing White Spot Lesions with P11-4: A three-arm trial
This trial tests whether applying the self-assembling peptide P11-4, alone or with fluoride varnish, can remineralize white spot lesions on permanent teeth in teens.
-
Chronic Cough and Airway Remodelling in Refractory Cough Patients
This study tests whether long-lasting chronic cough damages and remodels the airways in adults who have had cough for over a year and have not responded to prior treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.